An update on vitamin D3 analogues in the treatment of psoriasis

Skin Pharmacology and Applied Skin Physiology

Volumn 11, Issue 1, 1998, Pages 2-10

  Van De Kerkhof, P C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epidermis; Inflammation; Keratinization; Psoriasis; Treatment; Vitamin D3

Indexed keywords

CALCIPOTRIOL; CALCITRIOL; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; ETRETIN; LIGAND; TACALCITOL; VITAMIN D RECEPTOR; 1 ALPHA,24 DIHYDROXYVITAMIN D3; 1 ALPHA,24-DIHYDROXYVITAMIN D3; ANTIINFLAMMATORY AGENT; COLECALCIFEROL; DERMATOLOGICAL AGENT; DIHYDROXYCOLECALCIFEROL; DRUG DERIVATIVE;

ARTICLE; CELL PROLIFERATION; EPIDERMIS; EPIDERMIS CELL; HUMAN; KERATINIZATION; PRIORITY JOURNAL; PROMOTER REGION; PSORIASIS; PUVA; SKIN INFLAMMATION; TOPICAL DRUG ADMINISTRATION; TRANSCRIPTION REGULATION; DRUG EFFECT; INFLAMMATION; KERATINOCYTE; REVIEW;

ANTI-INFLAMMATORY AGENTS; CALCITRIOL; CHOLECALCIFEROL; DERMATOLOGIC AGENTS; DIHYDROXYCHOLECALCIFEROLS; HUMANS; INFLAMMATION; KERATINOCYTES; PSORIASIS;

EID: 0031596824     PISSN: 14222868     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029803     Document Type: Article

References (70)

1. Reed CL, Strunck HC, Steck IE: Other therapeutic applications of vitamin D; in Reed CL, Strunck HC. Steck IE (eds): Vitamin D Chemistry, Physiology, Pharmacology, Pathology, Experimental and Clinical Investigations. Chicago, University of Chicago, 1939, pp 312-313.
2. Degos R: Pustules. Dermatologie. Paris, Edition Médicales Flammarion, 1967, pp 458-496.
3. Morimoto S, Kumahara Y: Patient with psoriasis cured by 1α-hydroxyvitamin D3. Med J Osaka Uni 1985; 35:51.
4. 3. Arch Dermatol 1987; 123:1677-1683.
5. Luca de HF, Krisinger J, Darwish H: The vitamin D system 1990. Kidney Int Suppl 1990;29:S2-S8.
6. Collins ED, Normann AW: Vitamin D; in Machlin LJ (ed): Handbook of Vitamins. New York, Dekker, 1990, pp 59-98.
7. Kerkhof van de PCM: Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanism. Br J Dermatol 1995;132:675-682.
8. 3 receptor in the context of the nuclear receptor superfamily. Endocrine 1996;4:91-105.
9. Bugge TH, Pohl J, Lonnoy O, Stunnenberg HG: RXR-alpha, a promiscuous partner of retinoic acid and thyroid hormone receptors. EMBO J 1992;11:1409-1418.
10. Carlberg C, Bendik I, Wyss A: Two nuclear signalling pathways for vitamin D. Nature 1993;361:657-660.
11. 3 increases intracellular calcium in human keratinocytes. Br J Dermatol 1991;124: 230-235.
12. 3 increases intracellular free calcium in murine B16 melanoma. Br J Dermatol 1989;120:21-30.
13. Binderup L, Bramm E: Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro on calcium metabolism in vivo. Biochem Pharmacol 1988; 37:889-895.
14. 3 analogue, stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res 1990;282:164-167.
15. 3. Endocrinology 1983; 113:1950-1957.
16. 3 on the morphological and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1986;86: 709-714.
17. Holick MF: Vitamin D: Biosynthesis metabolism and mode of action; in De Groot LJ, Besser M, Burger HG (eds): Endocrinology. Philadelphia, Saunders, 1989, pp 902-926.
18. 3 homologs. J Med Chem 1992;35: 3280-3287.
19. Mørk Hansen Ch, Mathiasen IS, Binderup L: The anti-proliferative and differentiation-inducing effects of vitamin D analogs are not determined by the binding affinity for the vitamin D receptor alone. J Invest Dermatol, Symp Proc 1996;1:44-48.
20. 3 analogues: Studies of transfected human epidermal keratinocytes. J Invest Dermatol, Symp Proc 1996;1:105.
21. 3 in HL-60 cells. J Biol Chem 1990;265:2370-2374.
22. 3 regulation of transforming growth factor-β system in epithelial and fibroblastic cells: Relationship to plasminogen activation. J Invest Dermatol 1996;1:33-38.
23. 3 protects HL-60 cells against apoptosis but down-regulates the expression of the BCL-2 gene. Exp Cell Res 1993;209:367-374.
24. 3. J Cell Biochem 1992;49:26-31.
25. 3 to elicitation site. Arch Dermatol Res 1989;281:355-361.
26. 3: Preliminary evidence suggesting that interferon induces expression of the vitamin receptor. Haematologica 1991;76:467-471.
27. 3 down-regulation of HLA-DR on human peripheral blood monocytes. Immunology 1992;75:349-354.
28. 3. Nippon-Hifuka-Gakkai-Zasshi 1991;101: 519-525.
29. 3 and minerals on the synthesis of leukotriene 84 and 5-hydroxyeicosatetraenoic acid by rat peritoneal neutrophils. Prostaglandins Leukot Essent Fatty Acids 1988;32:9-14.
30. 3 analogue MC903: Modulations and interrelations. Br J Dermatol 1991;124:221-229.
31. 3) on cutanous inflammation, epidermal proliferation and keratinization in psoriasis: A placebo-controlled, double-blind study. Br J Dermatol 1994;131:57-63.
32. Gerritsen MJP, Rulo HFC, van Vlijmen-Willems IMJJ: Topical treatment of psoriatic plaques with 1,25-dihydroxycholecalciferol: A cell biological study. Br J Dermatol 1993; 128:666-673.
33. 3: A multiparameter flowcytometrical analysis of epidermal growth, differentiation and inflammation. Acta Derm Venereol, in press.
34. Murdoch D, Clissold SP: Calcipctriol, a review of its pharmacological properties and therapeutic use in psoriasis vulgaris. Drugs 1992;43: 415-429.
35. 3 in psoriasis vulgaris. Br J Dermatol 1986;115:421-429.
36. Smith EL, Pincus SH, Donovan L, Holick MF: A novel approach for the evaluation and treatment of psoriasis. J Am Acad Dermatol 1988; 19:516-528.
37. Langner A, Ashton P, Kerkhof PCM van de, Verjans A: A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. Br J Dermatol 1996;135:385-389.
38. 3 for the treatment of psoriasis: Review of the literature. Eur J Dermatol 1993;3:255-261.
39. TV-02 Ointment Research Group: Double blind, right/left comparison of TV-02 ointment and betamethason valerate in the treatment of psoriasis. Nishinihon J Dermatol 1989; 51:963-969.
40. Baadsgaard O, Traulsen J, Roed-Petersen J, Jakobsen HB: Optimal concentration of tacalcitol in once-daily treatment of psoriasis. J Dermatol Treat 1995;6:145-150.
41. Kerkhof PCM van de, Werfel T, Haustein UF, Luger T, Czarnetzki BM, Nieman R, Plänitz-Slenzel V: Tacalcitol ointment in the treatment of psoriasis vulgaris: A multicentre, placebo-controlled, double-blind study on efficacy and safety. Br J Dermatol 1996;135:758-765.
42. Gerritsen MJP, Glade CP, Luger Th, Werfel Th, Klüss B: Long-term efficacy and safety of once daily treatment with tacalcitol ointment in chronic plaque psoriasis. Dermatology, in press.
43. Kragballe K, Beck HI, Sogaard H: Improvement of psoriasis by a topical vitamin D3 analogue (MC903) in a double-blind study. Br J Dermatol 1988;119:223-230.
44. Kragballe K: Treatment of psoriasis by the topical application of the novel calcipotriol analogue calcipotriol (MC903). Arch Dermatol 1989;125: 1647-1652.
45. Staberg B, Roed-Peteresen J, Menné T: Efficacy of topical treatment in psoriasis with MC903, a new vitamin D analogue. Acta Derm Venereol (Stockh) 1989;69:147-150.
46. Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, Chevrant-Breton J, Beylot E, Bazex JA, Jürgensen HJ: Efficacy and safety of calcipotriol (MC903) ointment in psoriasis vulgaris. J Am Acad Dermatol 1992;27:983-988.
47. Ramsay CA, Berth-Jones J, Brundin G, Cunliffe WJ, Dubertret L, van de Kerkhof PCM, Menné T, Wegmann E: Long-term use of topical calcipotriol in chronic plaque-type psoriasis. Dermatology 1994;189:260-264.
48. Kragballe K, Tore Gjertzen B, Hoop D: Double blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991;337:193-196.
49. Cunliffe WJ, Berth-Jones J, Claudy A, Fairiss G, Goldin D, Gratton D, Henderson CA, Holden CA, Maddin WS, Ortonne JP, Young M: Comparative study of calcipotriol (MC903) ointment and betamethason 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992;26:736-743.
50. Berth-Jones J, Chu AC, Dodd WAH, Ganpale M, Griffiths WAD, Haydey RP, Klaber MR, Murray SJ, Rogers S, Jurgensen HJ: A multicentre, parallel-group comparison of calcipotriol ointment and short contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992;127:266-271.
51. Kragballe K: Combination of topical calcipotriol (MC903) and UVB radiation for psoriasis vulgaris. Dermatologica 1990;181:211-214.
52. Molin L: Calcipotriol combined with phototherapy (UVB and PUVA) in the treatment of psoriasis (abstract). J Eur Acad Dermatol 1995;S5(suppl):184.
53. Kokelj F, Lavaroni G, Guadagnini A: UVB versus UVB plus calcipotriol (MC903) therapy for psoriasis vulgaris. Acta Derm Venereol (Stockh) 1995;75:386-387.
54. Koo J: Phototherapy in combination with vitamin D therapy (abstract). Proc Clin Dermatol 2000, May 1996, Vancouver, p 88.
55. Kerscher M, Volkenandt M, Plewig G: Combination phototherapy of psoriasis with calcipotriol and narrowband UVB (letter). Lancet 1993; 343:923.
56. Frappaz A, Thivolet J: Calciprotiol in combination with PUVA: A randomized double-blind placebo study in severe psoriasis. Eur J Dermatol 1993;3:351-354.
57. Kerkhof PCM van de: Calcipotriol cream and concurrent corticosteroids in psoriasis (abstract). J Eur Acad Dermatol Venereol 1995; S5(suppl):184.
58. Ortonne JP: Psoriasis: New therapeutic modality by calcipotriol and betamethason dipropionate. Nouv Dermatol 1994;13:746-751.
59. Bruse S, Epinette WW, Funicella T, Son A, Jones EL, Los R, McPhee ME, Whitmore C: Comparative study of calcipotriene (MC903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994;31:755-759.
60. Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, Amblard P, Belaich S, de Belilovsky C, de la Brassine M, Martinet C, Bazex JA, Beylot C, Combemale P, Lambert D, Ostojnic A, Denooeux JP, Lauret Ph, Vaillant L, Weber M, Pamphile R, Dubertret L: A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: Results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994;31:68-74.
61. Kerkhof PCM van de, Hutchinson PE: Topical use of calcipotriol improves outcome in acitretin treated patients with severe psoriasis vulgaris (abstract). Br J Dermatol 1996; 135(suppl):30.
62. Kragballe K: Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC903). Arch Dermatol 1989; 125:1647-1652.
63. 3 analogue. Contact Dermatitis 1991;25:139-140.
64. Charles P: Effect of calcipotriol on calcium metabolism in psoriatic patients: A double blind controlled 3 weeks study (abstract). 2nd Int Sympon Calcipotriol, Monte Carlo. Monaco, 1993.
65. Siskin SB: A safety, efficacy, metabolic and bone density study of calcipotriol (abstract). 2nd Int Symp on Calcipotriol, Monte Carlo, Monaco, 1993.
66. Bourke JF, Berth-Jones J, Ingbal SJ, Hutchinson PE: High dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br J Dermatol 1993;129:74-76.
67. Dwyer C, Chapman RS: Calcipotriol and hypercalcaemia. Lancet 1991;338:764-765.
68. Bower M, Colston W, Stein RC: Topical calcipotriol treatment of advanced breast cancer. Lancet 1991; 337:701-702.
69. Hardman KH, Heath DA: Hypercalcaemia associated with calcipotriol (Dovonex) treatment (letter). Br Med J 1993;306:896.
70. Russell S, Young MJ: Hypercalcaemia during treatment of psoriasis with calcipotriol. Br J Dermatol 1994;130:795-796.